164,900 Shares in Qiagen N.V. $QGEN Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. purchased a new stake in Qiagen N.V. (NYSE:QGEN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 164,900 shares of the company’s stock, valued at approximately $7,932,000. Jupiter Asset Management Ltd. owned approximately 0.07% of Qiagen as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of QGEN. Envestnet Asset Management Inc. purchased a new position in Qiagen during the first quarter valued at approximately $13,463,000. New York State Common Retirement Fund raised its holdings in shares of Qiagen by 3.0% during the first quarter. New York State Common Retirement Fund now owns 125,126 shares of the company’s stock worth $5,024,000 after acquiring an additional 3,623 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in Qiagen during the first quarter valued at $3,029,000. Segall Bryant & Hamill LLC boosted its position in Qiagen by 15.8% during the first quarter. Segall Bryant & Hamill LLC now owns 175,656 shares of the company’s stock valued at $7,053,000 after purchasing an additional 23,967 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Qiagen in the first quarter valued at about $94,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Cowen reaffirmed a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. UBS Group lifted their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Barclays set a $53.00 price target on shares of Qiagen and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $49.69.

Qiagen Stock Performance

NYSE:QGEN opened at $44.65 on Friday. The firm has a market capitalization of $9.92 billion, a PE ratio of 26.38, a PEG ratio of 2.48 and a beta of 0.64. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The firm’s fifty day simple moving average is $46.25 and its 200 day simple moving average is $46.51.

Qiagen (NYSE:QGEN) last released its earnings results on Tuesday, November 4th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.03. The firm had revenue of $533.00 million during the quarter, compared to analyst estimates of $525.68 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.57 EPS. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. On average, sell-side analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.